Etoposide Recruiting Phase 2 Trials for AIDS-Related Burkitt Lymphoma / Recurrent Adult Burkitt Lymphoma / High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / Recurrent Childhood Acute Lymphoblastic Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Recurrent Burkitt Lymphoma / Acute Lymphoblastic Leukaemia Recurrent / Refractory Burkitt Lymphoma / Leukemias / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Burkitt Lymphoma / Atypical Burkitt/Burkitt-Like Lymphoma / Refractory Childhood Acute Lymphoblastic Leukemia / Refractory Acute Lymphoblastic Leukemia Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02199184Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT02385110Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis